Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rucaparib camsylate by Pharmaand for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Rucaparib camsylate is under clinical development by Pharmaand and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
Rucaparib camsylate by Pharmaand for Malignant Mesothelioma: Likelihood of Approval
Rucaparib camsylate is under clinical development by Pharmaand and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase...
Rucaparib camsylate by Pharmaand for Cervical Cancer: Likelihood of Approval
Rucaparib camsylate is under clinical development by Pharmaand and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
Rucaparib camsylate by Pharmaand for Metastatic Biliary Tract Cancer: Likelihood of Approval
Rucaparib camsylate is under clinical development by Pharmaand and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Rucaparib camsylate by Pharmaand for Metastatic Pancreatic Cancer: Likelihood of Approval
Rucaparib camsylate is under clinical development by Pharmaand and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Rucaparib camsylate by Pharmaand for Renal Cell Carcinoma: Likelihood of Approval
Rucaparib camsylate is under clinical development by Pharmaand and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...
Rucaparib camsylate by Pharmaand for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Rucaparib camsylate is under clinical development by Pharmaand and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...